autosomal dominant polycystic kidney disease

Sanofi's venglustat fails another trial, ending pursuit of kidney disease
Fierce Biotech
Tue, 06/1/21 - 11:02 am
Sanofi
venglustat
autosomal dominant polycystic kidney disease
kidney disease
clinical trials
Otsuka 'Big Kidney' campaign targets HCPs in bid to shift diagnostic standards
Fierce Pharma
Mon, 03/1/21 - 11:06 am
kidney disease
Otsuka
physicians
autosomal dominant polycystic kidney disease
pharma marketing
Palladio bags $20 million Series B to topple a problematic kidney disease drug
Endpoints
Fri, 09/25/20 - 10:33 am
Palladio Biosciences
autosomal dominant polycystic kidney disease
kidney disease
lixivaptan
Otsuka
Samsca
Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD
Pharmaceutical Business Review
Thu, 06/6/19 - 12:09 pm
Reata Pharmaceuticals
ADPKD
autosomal dominant polycystic kidney disease
Bardoxolone
orphan drugs
FDA
FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
CP Wire
Wed, 04/25/18 - 09:37 am
Otsuka
Jynarque
autosomal dominant polycystic kidney disease
FDA Approves Otsuka's Jynarque as First Treatment to Kidney Decline in Rapidy Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Wed, 04/25/18 - 09:36 am
Otsuka
Jynarque
autosomal dominant polycystic kidney disease
Otsuka's tolvaptan gets priority review at FDA
Pharma Times, UK
Mon, 04/15/13 - 09:36 am
Tolvaptan
Otsuka
FDA
autosomal dominant polycystic kidney disease
FDA Agrees to Priority Review for First ADPKD Therapy
Monthly Prescribing Reference
Sat, 04/13/13 - 12:15 pm
Tolvaptan
autosomal dominant polycystic kidney disease
Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
Business Wire
Sun, 11/4/12 - 10:54 am
Otsuka
Tolvaptan
autosomal dominant polycystic kidney disease
kidney disease